Study guide
10.2 Antihypertensive Pharmacology & Exercise Hemodynamics
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
10.2 Antihypertensive Pharmacology & Exercise Hemodynamics
Key Takeaways Explain This Topic AI
Beta-1 adrenergic receptor antagonists (e.g., metoprolol, carvedilol) blunt resting and exercise heart rates and systolic blood pressure by 20% to 30%, invalidating age-predicted target heart rate formulas and necessitating the use of the Borg Rating of Perceived Exertion (RPE 11–14) for exercise prescription.
Beta-blockers suppress sympathetically mediated warning signs of acute hypoglycemia (tachycardia, tremor, palpitations), leaving diaphoresis (cholinergically mediated sweating) as the primary clinical indicator of hypoglycemia in diabetic participants.
ACE inhibitors and ARBs reduce systemic vascular resistance and left ventricular afterload without blunting exercise heart rate; up to 20% of patients receiving ACE inhibitors develop a persistent, dry bradykinin-mediated cough requiring cross-titration to an ARB.
Dihydropyridine calcium channel blockers (e.g., amlodipine) act selectively on peripheral vascular smooth muscle to induce vasodilation and dependent pedal edema without chronotropic suppression, whereas non-dihydropyridines (diltiazem, verapamil) depress AV nodal conduction and myocardial contractility, blunting exertional heart rate.
Peripheral vasodilators and alpha-1 blockers abolish compensatory vasoconstriction in dependent extremities, demanding an extended 5 to 10 minute active gradual cool-down to prevent post-exercise venous pooling and profound orthostatic syncope.
Last updated: September 2026
10.2 Antihypertensive Pharmacology & Exercise Hemodynamics
Note
Pharmacological Surveillance Mandate : Nearly every patient entering Phase II cardiac rehabilitation is prescribed multi-agent antihypertensive regimens. Clinicians must master drug mechanisms, anticipated exertional hemodynamic shifts, and adverse side-effect profiles to tailor exercise prescriptions, detect drug-induced instability, and prevent post-exercise syncope.
Antihypertensive pharmacotherapy lowers systemic vascular resistance, reduces blood volume, or modulates cardiac chronotropy and inotropy. While these mechanisms confer potent cardioprotection, they significantly alter hemodynamic responses to acute aerobic and resistance exercise. Understanding drug-exercise interactions allows clinicians to formulate safe, individualized exercise prescriptions.
Beta-Adrenergic Antagonists: Chronotropic Blunting & Glycemic Masking
Beta-blockers represent cornerstone therapy following acute myocardial infarction (AMI), coronary revascularization, and in heart failure with reduced ejection fraction (HFrEF).
Pharmacological Subclasses
Cardioselective Beta-1 Blockers (e.g., Metoprolol succinate/tartrate, Atenolol, Bisoprolol ): Selectively antagonize β 1 \beta_1 β 1 -adrenergic receptors in cardiac nodal and myocardial tissue at standard doses, decreasing adenylyl cyclase activity and cyclic AMP (cAMP) production. This reduces resting and exercise sinus rates, AV nodal conduction velocity, and myocardial contractile force.
Non-Selective Beta Blockers (e.g., Propranolol, Nadolol ): Block both β 1 \beta_1 β 1 and β 2 \beta_2 β 2 receptors. Antagonism of vascular and bronchial β 2 \beta_2 β 2 receptors can induce peripheral vasoconstriction and bronchospasm in susceptible asthmatic patients.
Vasodilating Beta Blockers (e.g., Carvedilol, Labetalol, Nebivolol ): Carvedilol and labetalol provide combined non-selective beta-blockade plus peripheral α 1 \alpha_1 α 1 -adrenergic blockade , inducing systemic arterial vasodilation. Nebivolol provides selective β 1 \beta_1 β 1 -blockade paired with endothelial nitric oxide-mediated vasodilation, resulting in less peripheral coldness and erectile dysfunction.
Exercise Hemodynamic Consequences & RPE Prescription
Chronotropic and Inotropic Attenuation : Beta-blockers reduce resting heart rate by 10 to 15 bpm and peak exercise heart rate and systolic blood pressure by 20% to 30% . Rate-pressure product (RPP) is markedly lowered, elevating the ischemic threshold and preventing exertional angina.
Invalidation of Age-Predicted Formulas : Traditional formulas (e.g., 220 − age 220 - \text{age} 220 − age , Tanaka, Karvonen Heart Rate Reserve) markedly overestimate exercise target heart rates in beta-blocked patients. A patient with a theoretical max HR of 160 bpm may peak at only 118 bpm.
Prescription Mandate : Exercise intensity must be guided by measured parameters from an on-medication graded exercise test (GXT) or, more commonly, by the Borg 6–20 Rating of Perceived Exertion (RPE) scale. Clinicians target an RPE of 11 to 14 ("light" to "somewhat hard") , which corresponds closely to 40% to 70% of peak aerobic capacity despite severe chronotropic blunting.
Masking of Hypoglycemic Symptoms in Diabetes
In patients with concurrent diabetes mellitus, catecholamines normally trigger early warning signs of acute hypoglycemia: tachycardia, palpitations, anxiety, and tremors mediated via β \beta β -adrenergic receptors. Beta-blockers blunt these neurogenic warning signs , placing patients at risk of undetected neuroglycopenic coma. Crucially, diaphoresis (profuse sweating) is mediated by sympathetic cholinergic fibers acting on muscarinic receptors and is not blocked by beta-antagonists . Clinicians must teach diabetic patients that sweating is their primary symptom of hypoglycemia and mandate pre- and post-exercise blood glucose monitoring.
Renin-Angiotensin-Aldosterone System (RAAS) Blockers
ACE inhibitors and Angiotensin II Receptor Blockers (ARBs) represent first-line antihypertensive therapy in patients with diabetes, chronic kidney disease, myocardial infarction, and systolic dysfunction.
Mechanisms & Hemodynamic Profile
ACE Inhibitors (e.g., Lisinopril, Enalapril, Ramipril ): Inhibit the angiotensin-converting enzyme (kininase II), preventing conversion of angiotensin I to the potent vasoconstrictor angiotensin II and suppressing aldosterone secretion.
Angiotensin Receptor Blockers (ARBs) (e.g., Losartan, Valsartan, Candesartan ): Selectively block the angiotensin II type 1 ( AT 1 \text{AT}_1 AT 1 ) receptor, mitigating vasoconstriction, aldosterone release, and vascular remodeling without inhibiting kininase II.
Exercise Hemodynamics : RAAS blockers lower resting and exercise systolic and diastolic blood pressure through systemic afterload reduction without blunting normal exercise chronotropic or inotropic responses. Peak heart rate and stroke volume remain uninhibited.
Adverse Effects: Bradykinin Cough & Orthostasis
The ACEi Cough : Inactivation of kininase II by ACE inhibitors causes accumulation of bradykinin and substance P in the pulmonary tree, provoking a persistent, dry, hacking nocturnal cough in 5% to 20% of patients. This side effect is completely non-cardiac but frequently mistaken by patients for congestive heart failure. Treatment requires cross-titration to an ARB , which does not impede bradykinin breakdown.
Angioedema : A rare (0.1–0.7%) but potentially lethal complication of ACE inhibitors characterized by rapid non-pitting swelling of the lips, tongue, pharynx, and airway; absolute contraindication to rechallenge.
Post-Exercise Orthostasis : By blocking angiotensin-mediated compensatory vasoconstriction, ACE inhibitors and ARBs predispose patients to post-exercise hypotension if exertion ceases abruptly.
Calcium Channel Blockers (CCBs): Dihydropyridines vs. Non-Dihydropyridines
Calcium channel blockers inhibit voltage-gated L-type calcium channels in vascular smooth muscle and cardiac myocytes, sub-divided into two clinically distinct pharmacological classes:
CCB Subclass Prototype Agents Primary Target Tissue Resting & Exercise HR Contractility / Inotropy Common Clinical Side Effects
Dihydropyridines Amlodipine, Nifedipine, Felodipine Peripheral vascular smooth muscle (arteriolar beds) No change (or slight reflex tachycardia) No clinical depression (safe in preserved EF) Dependent peripheral pedal edema (precapillary dilation), facial flushing, headache, dizziness.
Non-Dihydropyridines Diltiazem, Verapamil Sinoatrial node, AV node, and ventricular myocardium Significantly blunted (↓10–25 bpm) Negative inotrope (contraindicated in HFrEF) Bradycardia, first- to third-degree AV block, constipation (verapamil), exacerbation of systolic heart failure.
Exercise Implications
Amlodipine and Dihydropyridines : Preserve normal chronotropic competence during exercise testing. The hallmark side effect—dependent pedal edema—results from preferential arteriolar vasodilation increasing capillary hydrostatic pressure; it is not fluid overload and does not respond to loop diuretics.
Diltiazem and Verapamil : Cause significant negative chronotropy and inotropy. When co-administered with beta-blockers, they carry a high risk of profound symptomatic sinus bradycardia, severe AV block, or asystole during rehabilitation sessions.
Diuretic Agents & Mineralocorticoid Receptor Antagonists
Diuretics mobilize sodium and water through renal tubule transport inhibition, altering plasma volume, stroke volume, and serum electrolytes:
Thiazide & Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone ):
Inhibit the Na + / Cl − \text{Na}^+/\text{Cl}^- Na + / Cl − cotransporter in the distal convoluted tubule.
Electrolyte Shifts : Promote renal potassium and magnesium wasting, leading to hypokalemia (<3.5 mEq/L) and hypomagnesemia , which trigger myocardial membrane instability, PVCs, and dangerous ventricular tachydysrhythmias during exercise.
Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide ):
Inhibit the Na + / K + / 2 Cl − \text{Na}^+/\text{K}^+/2\text{Cl}^- Na + / K + /2 Cl − symporter in the thick ascending limb of the loop of Henle. Highly potent natriuretics used primarily in volume-overloaded heart failure patients.
Volume Depletion & Hypotension : Over-diuresis reduces left ventricular end-diastolic volume (preload), producing exertional lightheadedness, hemoconcentration, and reflex tachycardia.
Potassium-Sparing Diuretics & MRAs (e.g., Spironolactone, Eplerenone ):
Competitive antagonists of aldosterone receptors in the cortical collecting tubule, preventing sodium retention and potassium secretion.
Hyperkalemia Risk : Can cause dangerous hyperkalemia (>5.0–5.5 mEq/L) , particularly when co-prescribed with ACE inhibitors or in chronic kidney disease, predisposing to peaked T waves, widened QRS complexes, and heart block.
Vasodilators, Alpha-Blockers & The Active Cool-Down Mandate
Peripheral vasodilators (e.g., Hydralazine, Nitrates ) and selective α 1 \alpha_1 α 1 -adrenergic blockers (e.g., Doxazosin, Prazosin, Terazosin ) reduce peripheral vascular resistance by relaxing vascular smooth muscle. Sustained Exercise ───> Widespread Skeletal Muscle Vasodilation
- │
- Abrupt Stoppage ───────> Loss of Skeletal Muscle Venous Pump + Blocked Sympathetic Tone
- │
- Result ────────────────> Massive Venous Pooling ───> Precipitous Preload Drop ───> Syncope
- The Post-Exercise Syncope Cascade
During exercise, up to 80% of cardiac output is shunted to active skeletal muscle beds. Venous return to the heart depends critically on the rhythmic compressive action of contracting skeletal muscles (the muscle pump) . If a patient receiving vasodilators or alpha-blockers stops exercising abruptly (e.g., standing still immediately after stepping off a treadmill):
Blood pools massively in dilated capacitance veins of the lower limbs.
Vasodilators and alpha-blockers prevent rapid reflex vasoconstriction.
Venous return (preload) drops precipitously, collapsing stroke volume and cerebral perfusion pressure, resulting in orthostatic syncope .
Clinical Prevention
Clinicians must mandate an extended active, gradual cool-down of at least 5 to 10 minutes at low workloads (e.g., slow walking at 1.5 mph or unresisted pedaling) to maintain the skeletal muscle pump while systemic vascular resistance gradually readjusts.
Clinical Scenario: Polypharmacy & Post-Exercise Presyncope
Clinical Encounter : A 67-year-old male post-PCI for stable angina is enrolled in Phase II CR. His medication regimen includes metoprolol tartrate 50 mg BID, amlodipine 10 mg daily, lisinopril 20 mg daily, and doxazosin 4 mg at bedtime. During session #4, he completes 25 minutes of cycling at 60 watts (HR 92 bpm, SBP 132/78 mmHg, RPE 12). He immediately steps off the bike to walk toward the water fountain, takes four steps, and collapses into a chair with grey pallor, yawning, and diaphoresis. Telemetry shows sinus rhythm at 58 bpm; manual blood pressure is 74/48 mmHg .
Analysis & Intervention :
Mechanism : The patient experienced severe post-exercise orthostasis caused by the combination of active skeletal muscle vasodilation, peripheral α 1 \alpha_1 α 1 -blockade (doxazosin), arteriole dilation (amlodipine), and afterload reduction (lisinopril), combined with abrupt cessation of the muscle pump. The beta-blocker prevented compensatory tachycardia.
Immediate Action : Clinicians immediately place the patient in the supine position with legs elevated above heart level, restoring venous return. Within 3 minutes, blood pressure rises to 110/68 mmHg, and mental clarity returns.
Permanent Protocol Modification : The patient's exercise prescription is amended to enforce a mandatory 8-minute gradual active cycling cool-down at zero resistance, followed by seated blood pressure checks before standing.